Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 12/6/13 → 12/7/16 |
Funding
- Vertex Pharmaceuticals Incorporated: $178,110.71
A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-Term Treatment with Lumacaftor in Combination with Ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mut
- Frederick, Carla (PI)
Project: Research